article thumbnail

Reassessing the role of tricuspid valve surgery in the modern era

Heart BMJ

The tricuspid valve (TV), historically deemed the ’forgotten valve’, is undergoing a renaissance as mounting evidence highlights its critical role in cardiovascular outcomes. TR: the clinical burden and the need for recalibration TR has been underestimated in its impact on morbidity and mortality. 2 3 Furthermore, persistent.

article thumbnail

Smidt Heart Institute Physicians Advance Transcatheter Tricuspid Valve Replacement

DAIC

Physicians in the Smidt Heart Institute at Cedars-Sinai have pioneered using a catheter-based approach to treat patients with tricuspid valve disease. The first 100 minimally invasive tricuspid procedures were done as part of the TRISCEND II clinical trial. Image by Getty. Image by Getty. Eduardo Marbán, MD, PhD.

Tricuspid 105
article thumbnail

Common Imaging Test Uses AI to Help Identify Heart Valve Disease

DAIC

tim.hodson Wed, 04/16/2025 - 14:19 April 16, 2025 An artificial intelligence (AI) program trained to review images from a common medical test can detect early signs of tricuspid heart valve disease and may help doctors diagnose and treat patients sooner, according to research from the Smidt Heart Institute at Cedars-Sinai.

article thumbnail

Atlantic Health System’s Morristown Medical Center Treats First Patient in New Jersey with Edwards’ EVOQUE Tricuspid Valve Replacement

DAIC

milla1cf Thu, 04/25/2024 - 17:21 April 25, 2024 — Atlantic Health System ’s Morristown Medical Center treated the first patient in New Jersey using Edwards Lifesciences EVOQUE tricuspid valve replacement, the first transcatheter therapy to receive U.S. According to National Institutes of Health an estimated 1.6 million people in the U.S.

Tricuspid 111
article thumbnail

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

DAIC

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100
article thumbnail

Contemporary evaluation and treatment of tricuspid regurgitation

Frontiers in Cardiovascular Medicine

Valvular heart disease is a global health burden with substantial mortality. The left-sided valvular diseases have been extensively described using the robust treatment strategies available.

article thumbnail

Atrial Fibrillation Ablation in Congenital Heart Disease: Therapeutic Challenges and Future Perspectives

Journal of the American Heart Association

The increasing prevalence of atrial fibrillation (AF) in adults with congenital heart disease raises significant questions regarding its management. The unique underlying anatomic and physiological background further adds to the difficulty in eliminating the AF burden in these patients.